What does CUSIP 05338F306 represent in this 13F holders report?

CUSIP 05338F306 is the security identifier for AVTX - Avalo Therapeutics, Inc. - COMMON STOCK used to aggregate holder disclosures.

How many institutions held AVTX - Avalo Therapeutics, Inc. - COMMON STOCK in Q4 2025?

84 institutional investors reported AVTX - Avalo Therapeutics, Inc. - COMMON STOCK for Q4 2025. Use the holders table for investor-level position and value details.

Avalo Therapeutics, Inc. - COMMON STOCK (AVTX)

CUSIP: 05338F306

Q4 2025 13F Holders as of 31 Dec 2025

Type / Class: Equity / COMMON STOCK
Shares outstanding: 22,853,024
Total 13F shares: 19,885,517
Share change: +4,156,297
Total reported value: $361,121,251
Put/Call ratio: 59%
Price per share: $18.16
Number of holders: 84
Value change: +$79,863,888
Number of buys: 57
Number of sells: 27

Quarterly Holders Quick Answers

What is CUSIP 05338F306?
CUSIP 05338F306 identifies AVTX - Avalo Therapeutics, Inc. - COMMON STOCK in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q1 2026
Previous quarter: Q3 2025

Recent filing periods for CUSIP 05338F306:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of AVTX - Avalo Therapeutics, Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
RA CAPITAL MANAGEMENT, L.P.	13D/G 13F	Company	9.9%	1,939,065	$32,867,152	+$9,371,621	31 Dec 2025	13D/G 13F
BIOTECHNOLOGY VALUE FUND L P	13D/G	BVF PARTNERS L P/IL	10%	1,904,257	$32,277,156	+$7,561,497	31 Dec 2025	13D/G
ORBIMED ADVISORS LLC	13D/G 13F	Company	6.4%	1,187,300	$20,124,735	+$3,734,085	31 Dec 2025	13D/G 13F
BVF INC/IL	13F	Company	5.9%	1,355,256	$17,225,304	—	30 Sep 2025	13F
Nantahala Capital Management, LLC	13D/G 13F	Company	9.4%	1,235,000	$15,696,850	+$4,257,850	30 Sep 2025	13D/G 13F
Caligan Partners LP	13D/G 13F	Company	4.9%	881,533	$14,941,984	+$816,990	31 Dec 2025	13D/G 13F
VANGUARD GROUP INC	13D/G 13F	The Vanguard Group · Company	4.4%	804,084	$14,602,165	+$2,023,878	31 Dec 2025	13D/G 13F
Point72 Asset Management, L.P.	13F 13D/G	Company	3.5% from 13D/G	1,053,983	$13,396,124	—	30 Sep 2025	13F 13D/G
Affinity Asset Advisors, LLC	13F	Company	4.4%	1,006,217	$12,789,018	—	30 Sep 2025	13F
BALYASNY ASSET MANAGEMENT L.P.	13F 13D/G	Company	2.4% from 13D/G	817,436	$10,389,612	—	30 Sep 2025	13F 13D/G
SILVERARC CAPITAL MANAGEMENT, LLC	13F 13D/G	Company	2.8% from 13D/G	720,922	$9,162,919	—	30 Sep 2025	13F 13D/G
Ikarian Capital, LLC	13D/G 13F	Company	3.8%	711,967	$9,049,101	-$6,100,673	30 Sep 2025	13D/G 13F
BANK OF AMERICA CORP /DE/	13F	Company	2.7%	605,842	$7,700,252	—	30 Sep 2025	13F
Commodore Capital LP	13F	Company	2.1%	483,000	$6,138,930	—	30 Sep 2025	13F
TCG Crossover Management, LLC	13F	Company	2.1%	483,000	$6,138,930	—	30 Sep 2025	13F
CITADEL ADVISORS LLC	13F	Company	2.1%	481,669	$6,122,013	—	30 Sep 2025	13F
Patrick J. Crutcher	13D/G	—	4.2%	549,467	$3,593,514	$0	06 Aug 2025	13D/G
Velan Capital Investment Management LP	13F	Company	1.2%	263,642	$3,350,890	—	30 Sep 2025	13F
ADAGE CAPITAL PARTNERS GP, L.L.C.	13F	Company	1.1%	258,769	$3,288,954	—	30 Sep 2025	13F
BOOTHBAY FUND MANAGEMENT, LLC	13F	Company	1%	228,297	$2,901,655	—	30 Sep 2025	13F
AMERIPRISE FINANCIAL INC	13F	Company	0.93%	213,572	$2,714,500	—	30 Sep 2025	13F
SUPERSTRING CAPITAL MANAGEMENT LP	13F	Company	0.82%	188,080	$2,390,497	—	30 Sep 2025	13F
Ally Bridge Group (NY) LLC	13F	Company	0.78%	178,100	$2,263,651	—	30 Sep 2025	13F
BlackRock, Inc.	13F	Company	0.67%	154,251	$1,960,531	—	30 Sep 2025	13F
Deep Track Capital, LP	13F	Company	0.63%	144,600	$1,837,866	—	30 Sep 2025	13F
PERCEPTIVE ADVISORS LLC	13F	Company	0.61%	139,667	$1,775,168	—	30 Sep 2025	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	0.6%	137,431	$1,746,748	—	30 Sep 2025	13F
Boxer Capital Management, LLC	13F	Company	0.55%	125,000	$1,588,750	—	30 Sep 2025	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.46%	104,189	$1,325,396	—	30 Sep 2025	13F
Exome Asset Management LLC	13F	Company	0.44%	100,036	$1,271,458	—	30 Sep 2025	13F
Patient Square Capital LP	13F	Company	0.44%	100,000	$1,271,000	—	30 Sep 2025	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.43%	98,700	$1,254,477	—	30 Sep 2025	13F
RWA WEALTH PARTNERS, LLC	13F	Company	0.38%	86,516	$1,099,618	—	30 Sep 2025	13F
CANTOR FITZGERALD, L. P.	13F	Individual	0.37%	85,247	$1,083,489	—	30 Sep 2025	13F
DLD Asset Management, LP	13F	Company	0.33%	75,000	$953,250	—	30 Sep 2025	13F
Aberdeen Group plc	13F	Company	0.32%	72,800	$925,288	—	30 Sep 2025	13F
Sio Capital Management, LLC	13F	Company	0.32%	72,173	$917,319	—	30 Sep 2025	13F
MARSHALL WACE, LLP	13F	Company	0.25%	56,009	$711,874	—	30 Sep 2025	13F
Quadrature Capital Ltd	13F	Company	0.24%	54,999	$695,737	—	30 Sep 2025	13F
TWO SIGMA INVESTMENTS, LP	13F	Company	0.22%	49,242	$625,866	—	30 Sep 2025	13F
SUSQUEHANNA INTERNATIONAL GROUP, LLP	13F	Company	0.21%	47,398	$602,429	—	30 Sep 2025	13F
STATE STREET CORP	13F	Company	0.2%	45,454	$577,720	—	30 Sep 2025	13F
UBS Group AG	13F	Company	0.2%	45,208	$574,594	—	30 Sep 2025	13F
Walleye Capital LLC	13F	Company	0.2%	44,743	$568,684	—	30 Sep 2025	13F
LANDSCAPE CAPITAL MANAGEMENT, L.L.C.	13F	Company	0.15%	33,337	$423,713	—	30 Sep 2025	13F
ADAR1 Capital Management, LLC	13F	Company	0.14%	32,393	$411,715	—	30 Sep 2025	13F
ARMISTICE CAPITAL, LLC	3/4/5	10%+ Owner	— class O/S missing	765,828	$397,771	—	26 Jun 2023	3/4/5
Birchview Capital, LP	13F	Company	0.14%	31,000	$394,010	—	30 Sep 2025	13F
HighVista Strategies LLC	13F	Company	0.12%	27,778	$353,058	—	30 Sep 2025	13F
PRELUDE CAPITAL MANAGEMENT, LLC	13F	Company	0.11%	24,628	$313,022	—	30 Sep 2025	13F

Institutional Holders of Avalo Therapeutics, Inc. - COMMON STOCK (AVTX) as of Q4 2025

As of 31 Dec 2025, Avalo Therapeutics, Inc. - COMMON STOCK (AVTX) was held by 84 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 19,885,517 shares. The largest 10 holders included BVF INC/IL, Nantahala Capital Management, LLC, ORBIMED ADVISORS LLC, Affinity Asset Advisors, LLC, Caligan Partners LP, VANGUARD GROUP INC, RA CAPITAL MANAGEMENT, L.P., MILLENNIUM MANAGEMENT LLC, Point72 Asset Management, L.P., and BANK OF AMERICA CORP /DE/. This page lists 84 institutional shareholders reporting positions in this security for the Q4 2025 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q4 2025 vs Q3 2025 Across Filers

Q3 2025 holders

Q4 2025 holders

Holder diff

Investor	Q3 2025 Shares	Q4 2025 Shares	Share Diff	Share Chg %	Q3 2025 Value $	Q4 2025 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.